Crohn’s Disease News and Research RSS Feed - Crohn’s Disease News and Research

Battling IBD with super heroes: an interview with Dr James Lindsay

Battling IBD with super heroes: an interview with Dr James Lindsay

Takeda Pharmaceutical Company Limited has launched IBD Unmasked as a first-of-its-kind global initiative designed to raise awareness of the unsung Super Heroes of the global IBD community. [More]
New hydrogel-based biochip may help in early diagnosis of bowel cancer

New hydrogel-based biochip may help in early diagnosis of bowel cancer

Researchers from the Moscow Institute of Physics and Technology, the Engelhardt Institute of Molecular Biology, the Institute of Bioorganic Chemistry and a number of other Russian research centers have developed a new method of diagnosing colorectal cancer. [More]
Could worm infection counter IBD? An interview with Dr Loke and Dr Cadwell

Could worm infection counter IBD? An interview with Dr Loke and Dr Cadwell

The hygiene hypothesis refers to the idea that decreased exposure to certain infectious agents (because of better hygiene) is the reason why we have seen an increase in inflammatory diseases in the developed world. [More]
Caltech researchers discover new potential cause for Crohn's disease

Caltech researchers discover new potential cause for Crohn's disease

The community of beneficial bacteria that live in our intestines, known as the gut microbiome, are important for the development and function of the immune system. There has been growing evidence that certain probiotics--therapies that introduce beneficial bacteria into the gut--may help alleviate some of the symptoms of intestinal disorders such as Crohn's disease. [More]
Genetic variations that prevent beneficial gut bacteria from working may lead to Crohn's disease

Genetic variations that prevent beneficial gut bacteria from working may lead to Crohn's disease

A major type of inflammatory bowel disease (IBD) may be caused in part by genetic variants that prevent beneficial bacteria in the gut from doing their job, according to a new study published today in the journal Science. [More]
Researchers develop computer model to reveal how antibiotic-resistant microbes develop and spread

Researchers develop computer model to reveal how antibiotic-resistant microbes develop and spread

Researchers from the Scientific Research Institute of Physical-Chemical Medicine, MIPT, the company M&S Decisions and the research department of Yandex have built a computer model of the interaction between different bacteria, and between bacteria and the gut wall. [More]
CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

CMGH study offers insight into future interventions for Crohn's disease, chronic pancreatitis

Cellular and Molecular Gastroenterology and Hepatology is committed to publishing impactful digestive biology research covering a broad spectrum of themes in GI, hepatology and pancreatology. We wanted to share two new CMGH articles, which both offer important insight into future interventions for chronic conditions. [More]
GEMINI LTS study: Patients with active ulcerative colitis report clinical improvements with vedolizumab treatment

GEMINI LTS study: Patients with active ulcerative colitis report clinical improvements with vedolizumab treatment

Takeda Pharmaceutical Company Limited, (“Takeda”) today announced that the interim findings from the GEMINI Long-Term Safety (LTS) study were presented during the 2016 European Crohn's and Colitis Organisation (ECCO) Annual Scientific Meeting in Amsterdam, The Netherlands. [More]
Real-world studies support switching IBD patients from reference infliximab to biosimilar infliximab

Real-world studies support switching IBD patients from reference infliximab to biosimilar infliximab

Data presented today at the 11th Congress of European Crohn’s and Colitis Organisation adds to the growing body of real-world evidence that supports switching patients from reference infliximab to biosimilar infliximab. [More]

Largest real world study to date demonstrate effectiveness of biosimilar infliximab in patients with inflammatory bowel diseases who have been switched from reference infliximab

Data from the PRospective Observational cohort Study on patients with Inflammatory bowel disease receiving Therapy with BIOsimilars (PROSIT-BIO) in patients with ulcerative colitis (UC) and Crohn’s disease (CD) has been presented at the Italian Group for the Study of IBD (IG-IBD), VII National Congress, Palermo, Italy. [More]
Stem cell therapy not significantly better than conventional treatment for Crohn's disease

Stem cell therapy not significantly better than conventional treatment for Crohn's disease

A clinical trial to test the effectiveness of a stem cell therapy among adults with difficult to treat Crohn's disease has found it is not significantly better than conventional treatment in producing sustained disease remission after one year. [More]
Hematopoietic stem cell transplantation does not provide improvement for patients with Crohn disease

Hematopoietic stem cell transplantation does not provide improvement for patients with Crohn disease

Among adults with difficult to treat Crohn disease not amenable to surgery, hematopoietic stem cell transplantation, compared with conventional therapy, did not result in significant improvement in sustained disease remission at l year and was associated with significant toxicity, according to a study in the December 15 issue of JAMA. [More]
ISCT launches publication and reference guide on Use of Unproven Cellular Therapies

ISCT launches publication and reference guide on Use of Unproven Cellular Therapies

The International Society for Cellular Therapy, the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients’ lives, today announces the launch of its publication and reference guide on the Use of Unproven Cellular Therapies. [More]
Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Lab expands access to new IBS test with national agreement with Quest

Commonwealth Laboratories, LLC ("Commonwealth") announced today that it has formed an agreement with Quest Diagnostics ("Quest") that will expand the availability of IBSchek™, a new laboratory developed blood test designed to help physicians quickly and reliably diagnose Irritable Bowel Syndrome (IBS). [More]
TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

TxCell reviews its manufacturing strategy to focus on R&D and strategic partnerships - its core, high added value businesses

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that it is operating a strategic review that should result in the outsourcing of all existing and future clinical and commercial manufacturing operations to contract manufacturing organizations (CMOs). [More]
Different Crohn's disease treatments affect children's gut microbes in distinct ways

Different Crohn's disease treatments affect children's gut microbes in distinct ways

Different treatments for Crohn's disease in children affects their gut mi-crobes in distinct ways, which has implications for future development of microbial-targeted therapies for these patients, according to a study led by researchers from the Perelman School of Medicine at the University of Pennsylvania. [More]
Researchers use new software tool to identify genetic overlaps between palmitoleic acid and Crohn's disease

Researchers use new software tool to identify genetic overlaps between palmitoleic acid and Crohn's disease

Some research has suggested that omega-3 fatty acids, abundant in fish oils, can relieve inflammation in Crohn's disease. But a new study using software developed by Duke scientists hints that we should be paying closer attention to what the other omegas -- namely, omega-6 and omega-7 -- are doing to improve or worsen the disease. [More]

FDA grants Fast Track Designation to TxCell’s Ovasave for treatment of Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has granted Fast Track Designation to TxCell’s lead product Ovasave for the treatment of moderate to severe Crohn’s disease. [More]
Groundbreaking experimental therapy has ability to suppress ulcerative colitis

Groundbreaking experimental therapy has ability to suppress ulcerative colitis

UCLA scientists have discovered a groundbreaking experimental therapy that has the ability to suppress the development of ulcerative colitis (UC), a disease which causes inflammation in the digestive tract and colon cancer. The treatment utilizes a chemical inhibitor able to block an RNA molecule (microRNA-214) involved in the transmission of genetic information. [More]

FDA accepts TxCell’s IND application for Ovasave for treatment of refractory Crohn’s disease

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells for severe chronic inflammatory and autoimmune diseases, announces today that the United States Food and Drug Administration has accepted TxCell’s Investigational New Drug application for the company’s lead product, Ovasave(R), currently in a phase 2b clinical trial for the treatment of patients with refractory Crohn’s disease. [More]
Advertisement
Advertisement